Introduction
Antiphospholipid antibodies (aPL) are a heterogeneous family of autoantibodies that are associated with thrombosis and recurrent pregnancy failure. In the general obstetric population, the prevalence of aPL is 1-7% (Lockwood et al., 1989; Pattison et al., 1993; Yasuda et al., 1995; Faden et al., 1997) , while in patients with a history of recurrent miscarriage, the frequency of aPL is up to 20% (Lockwood et al., 1989; MacLean et al., 1994; Oshiro et al., 1996; Jaslow et al., 2010) . Patients with aPL have an increased risk of transient ischemic attack, pulmonary embolism and deep vein thrombosis. In addition, aPL are also associated with stillbirth, preterm birth, pre-eclampsia and intrauterine growth restriction (Branch et al., 1989; Lockwood et al., 1989; Lynch et al., 1994; Yasuda et al., 1995; Faden et al., 1997; Magid et al., 1998; Aggarwal et al., 1999; Tincani et al., 2002; Duckitt and Harrington, 2005) . Patients who test positive for clinically relevant aPL and experience vascular thrombosis or pregnancy morbidity are defined as having the antiphospholipid antibody syndrome (APS) (Miyakis et al., 2006) .
Clinically relevant aPL include the lupus anticoagulant, anti-cardiolipin and anti-b 2 glycoprotein I antibodies. Despite what the name suggests, clinically relevant aPL bind to phospholipid binding proteins, rather than to phospholipids themselves. Antigens for aPL include b 2 glycoprotein I (b 2 GPI), prothrombin, annexin V, tissue factor and protein C (Galli et al., 1990; McIntyre et al., 1997; Chamley, 2002; Branch and Khamashta, 2003) . The most well-studied antigen is b 2 GPI, a highly abundant plasma protein. b 2 GPI must be immobilized on a negatively charged surface, such as the anionic phospholipid phosphatidylserine, before aPL may bind (Chamley et al., 1999) . Normally, phosphatidylserine is restricted to the inner leaflet of the plasma membrane and thus circulating b 2 GPI and aPL do not interact (Chamley, 2002) . However, when a cell becomes damaged, activated or apoptotic, phosphatidylserine is exteriorized on the outer leaflet of the plasma membrane, allowing b 2 GPI to bind. The binding of b 2 GPI to phosphatidylserine enables circulating aPL to bind to the cells and exert their pathogenic effects (Levine et al., 1998; Giles et al., 2003) . Antiphospholipid antibodies can also interact with a range of different cell types through cell surface receptors, including TLR2 (Satta et al., 2011) , TLR4 (Mulla et al., 2009 Marchetti et al., 2014) and apolipoprotein E receptor 2 (Pennings et al., 2006; Romay-Penabad et al., 2011; Brandt et al., 2013) .
The placenta is a crucial organ, derived largely from the fetus, that allows the exchange of nutrients, gases and wastes during pregnancy. Three types of specialized epithelial cells are found in the human placenta: the outermost syncytiotrophoblast, the underlying cytotrophoblasts and the extravillous trophoblasts. The syncytiotrophoblast is a large multinucleated cell that covers the entire surface of the placenta. It is terminally differentiated and is replenished by the fusion of underlying cytotrophoblasts in a process called syncytialization. Some cytotrophoblasts may also differentiate into extravillous trophoblasts which invade into the maternal decidua and anchor the placenta. Extravillous trophoblasts also invade into maternal spiral arteries, transforming them from narrow, vasoactive vessels to wide-bore, flaccid tubes (Brosens et al., 1967; Kam et al., 1999; Cartwright et al., 2010) . These physiological changes allow for effective exchange of nutrients and wastes between the mother and the fetus.
As a consequence of syncytialization, the syncytiotrophoblast constitutively exteriorizes phosphatidylserine on its cell surface (Lyden et al., 1993; Katsuragawa et al., 1997; Vogt et al., 1997; Rote et al., 1998) . There is also some evidence to suggest that extravillous trophoblasts exteriorize phosphatidylserine (Katsuragawa et al., 1997) . Trophoblasts also synthesize endogenous b 2 GPI (Chamley et al., 1997) , suggesting that there may be many sites for b 2 GPI/aPL binding on the surface of the human placenta (Blank et al., 1991; Chamley et al., 1993; La Rosa et al., 1994) .
With the placenta being a potential target for circulating aPL, it is not surprising that women with aPL may experience obstetric complications. The causal effects of aPL on obstetric morbidity were first demonstrated in murine studies which showed that the injection of human aPL into pregnant mice decreased fecundity and increased fetal resorption, placental necrosis and intrauterine growth restriction (Branch et al., 1990; Blank et al., 1991 Blank et al., , 1994 Ikematsu et al., 1998) . However, since the human placenta is structurally different from the murine placenta, the pathogenesis of aPL-related pregnancy morbidity in mice may not accurately reflect what happens in aPL-positive women (Radway-Bright et al., 1999) .
Since aPL are associated with systemic thrombosis, obstetric complications in patients with aPL were first attributed to thrombosis and infarction at the materno-fetal interface. Indeed, early reports of placentae from women with the lupus anticoagulant exhibited ischemic infarcts (de Castellarnau et al., 1988; De Wolf et al., 1982; Gardlund, 1984) . However, large-scale histological studies have since revealed that neither thrombosis nor infarction are common in the placentae of patients with the APS (Lockshin et al., 1985; Salafia and Cowchock, 1997; Sebire et al., 2002) . Specifically, the prevalence of intervillous thrombosis in women with aPL is similar to that found in aPL-negative pregnancies (Sheppard and Bonnar, 1981; Lockshin et al., 1985; Sebire et al., 2002) . Moreover, due to the presence of trophoblast plugs in the uterine spiral arteries, significant maternal blood flow does not occur in the intervillous space until the end of the first trimester, suggesting that placental thrombosis and infarction are unlikely causes of embryonic or early fetal loss in women with aPL.
A range of pathological lesions have since been reported in the placentae of women with aPL, including decidual vasculopathy, ischemic-hypoxic damage and several inflammatory lesions (Salafia and Cowchock, 1997; Salafia and Parke, 1997; Magid et al., 1998; Stone et al., 2006) . Defective endovascular trophoblast invasion and decreased transformation of the spiral arteries have also been observed (Salafia and Parke, 1997; Sebire et al., 2002) . Therefore, it is possible that aPL affect pregnancy outcome by affecting trophoblast function directly, rather than by promoting placental thrombosis and subsequent ischemic damage.
To better understand how aPL affect human pregnancy, trophoblasts or placental explants have been cultured with aPL in vitro. However, different studies have employed different trophoblast models and diverse culture conditions. Consequently, the definitive effects of aPL on trophoblasts are still unclear. We have conducted this systematic review of the literature to summarize published studies that have investigated the effects of aPL on trophoblast function in vitro. In addition, we have also systematically summarized the effects of pharmacological treatment on aPL-induced defects in trophoblast function in vitro. This will provide a more complete picture of the state of knowledge of the effects of aPL on trophoblast function in vitro and allow a better understanding of the mechanisms of actions of the different drugs currently used to treat obstetric APS.
Methods

Literature search
A systematic search was performed on PubMed, Scopus, Embase and Web of Science databases up to 25 April 2014. The search strategy: 'placenta OR trophoblast' AND 'antiphospholipid antibody OR antiphospholipid syndrome' was used. For these terms, all relevant keyword variants and subject headings were included. Results were limited to original records published in English. Reference lists at the end of each record were also searched for relevant articles.
Eligibility criteria
The titles and abstracts of all retrieved records were independently reviewed by two observers (C.A.V. and M.T.) to include studies that investigated the effects of aPL on trophoblast function in vitro. Records that qualified with this criterion were read by M.T. and all relevant experimental results were extracted. Studies were excluded based on the absence of an appropriate control group. Studies were discussed between M.T., C.A.V. and L.W.C. before exclusion.
Data extraction
Relevant experimental results were extracted from each of the included records, and the effects of aPL on trophoblast proliferation, death, syncytialization, invasion, hormone production, cytokine production, coagulation and complement activation were recorded by MT. The effects of pharmacological treatment on the function of aPL-treated trophoblasts were also recorded.
Results
Search results
A total of 1071 records were retrieved from Pubmed (289), Embase (192) , Scopus (292) and Web of Science (298). Seven additional records were manually added after reviewing the reference lists of relevant articles. After removing duplicates, the titles and abstracts of 529 articles were reviewed (Fig. 1 ). There were 327 records excluded as they did not report on the effects of aPL on trophoblast function in vitro, and 143 records were excluded as they contained no primary data. The full-text articles of 11 records were not available so these were also excluded from further analysis.
Finally, 48 articles were read and relevant experimental results were extracted from 47 articles. One study was excluded based on lack of an appropriate negative control (Pantham et al., 2012) .
The effects of aPL on trophoblast viability in vitro
Trophoblast proliferation
Seven studies reported on the effects of aPL on trophoblast proliferation in vitro (Table I) . Four studies showed that aPL decreased the proliferation of trophoblasts within placental explants in vitro (Yacobi et al., 2002; Ornoy et al., 2003; Bose et al., 2004; Schwartz et al., 2007) and a fifth study demonstrated a similar effect using the choriocarcinoma cell lines, JAR and BeWo (Chamley et al., 1998) . One study reported that aPL did not affect trophoblast proliferation (Mulla et al., 2009) , while another study showed that aPL increased the proliferation of HTR-8/ SVneo trophoblasts in vitro (Jovanovic et al., 2010) .
Trophoblast death
A total of 14 studies reported on the effects of aPL on trophoblast death in vitro (Table I) . Eight studies showed that aPL increased trophoblast death (Hasegawa et al., 1990; Di Simone et al., 2001; Yacobi et al., 2002; Ornoy et al., 2003; Bose et al., 2004; Chen et al., 2009; Schwartz et al., 2007; Mulla et al., 2009) , while five studies demonstrated that aPL had no effect on trophoblast death (Katsuragawa et al., 1997; Di Simone et al., 2006; Jovanovic et al., 2010; Ichikawa et al., 2011; Kovacevic et al., 2013) . One study showed that aPL increased the activity of caspase 3, 8 and 9 by extravillous trophoblasts (Mulla et al., 2009) , while another study reported reduced activity of caspase 3 and 7 in trophoblastic debris shed from placental explants cultured with aPL (Chen et al., 2009) . Increased levels of cytochrome c in the cytoplasm of placental explants treated with aPL and decreased expression of Bcl-2 and increased expression of Bax in trophoblasts treated with aPL have also been reported (Di Simone et al., 2006) .
The effects of aPL on trophoblast syncytialization in vitro
Syncytialization
Four studies have reported on the effects of aPL on syncytialization (Table II) . All four studies showed that aPL inhibited the syncytialization of cytotrophoblasts in vitro (Adler et al., 1995; Di Simone et al., 1999 , 2000a Marchetti et al., 2014) .
Another type of multinucleated cell found in the human placental bed are giant cells, which may be formed from the fusion of extravillous Figure 1 Flow diagram of the search strategy undertaken for this systematic review, based on the PRISMA criteria (Moher et al., 2009) Continued trophoblasts (al-Lamki et al., 1999) . One study investigated the effects of aPL on giant cell formation in vitro and found that aPL inhibited their formation (Quenby et al., 2005) .
Production of syncytiotrophoblast hormones
During pregnancy, the syncytiotrophoblast synthesizes hormones including human chorionic gonadotrophin (hCG) and steroid hormones. Thirteen studies investigated the effects of aPL on hCG production by trophoblasts and of these, 10 studies showed that aPL decreased basal and/or GnRH-stimulated hCG secretion (Table II) . Two studies reported that aPL did not affect hCG secretion by trophoblasts (Rand et al., 1994; Yacobi et al., 2002) and one study showed variable results depending on whether human or murine aPL were used (Shurtz-Swirski et al., 1993) . In that study, while aPL isolated from women with APS decreased hCG secretion, murine aPL increased hCG secretion (Shurtz-Swirski et al., 1993) . The secretion of human placental lactogen (hPL) was investigated in one study and it was reported that aPL reduced hPL secretion (Katsuragawa et al., 1997) . Two studies have reported on the effects of aPL on progesteronee production by trophoblasts. While one study showed that treatment with aPL increased progesteronee secretion (Yacobi et al., 2002) , another study reported that progesteronee secretion was not affected by treatment with aPL (Schwartz et al., 2007) . Estrogen secretion by trophoblasts was also not affected by treatment with aPL (Schwartz et al., 2007) .
The effects of aPL on trophoblast invasion in vitro
Fourteen studies investigated the effects of aPL treatment on trophoblast invasion and all 14 studies observed an inhibition of trophoblast invasion by aPL in vitro (Table III) .
Trophoblast invasion requires the expression of several key proteins, including cell-surface adhesion molecules and matrix metalloproteinases.
Two studies reported that treatment of trophoblasts with aPL altered the trophoblastic expression pattern of integrins and cadherins (Di Simone et al., 2002; Kovacevic et al., 2013) and two studies showed that treatment with aPL decreased trophoblastic expression of matrix metalloproteinases (Di Simone et al., 2010b; Kovacevic et al., 2013) . Another study showed that treatment with aPL impaired the adhesion between cytotrophoblasts and endothelial cells, which may be an important interaction during invasion of the spiral arteries (Bulla et al., 1999) .
The effects of aPL on the secretion of signalling molecules by trophoblasts
One group of signalling molecules that are of particular interest to pregnancy morbidity are angiogenic factors, such as placental growth factor (PIGF), vascular endothelial growth factor (VEGF) and soluble Fms-like kinase 1 (sFlt-1). Two studies have investigated the effects of aPL treatment on PIGF secretion by trophoblasts. One study showed that aPL increased PIGF secretion from HTR8/SVneo cells (Carroll et al., 2011) , while another study showed that aPL inhibited PIGF secretion from JEG-3 cells (Ichikawa et al., 2011) . Similarly, one study showed that treatment with aPL increased the secretion of VEGF by trophoblasts (Carroll et al., 2011) , while another study showed no change (Ichikawa et al., 2011) . The effects of aPL on the secretion of sFlt-1 were also ambiguous; one study reported that aPL did not affect its secretion (Ichikawa et al., 2011) , while another reported that thedetrimental effects of aPL on sFlt-1 secretion were dependent on the aPL epitope (Carroll et al., 2011) .
In one study (Mulla et al., 2009) , the effects of aPL treatment on the production of several pro-and anti-inflammatory cytokines from trophoblasts were reported. For a comprehensive list of the effects of aPL on cytokine production by trophoblasts, the reader is referred to Table IV. Of note, two studies reported that aPL increased IL-1b secretion by trophoblasts (Mulla et al., 2009 Treatment of trophoblasts with aPL also increased trophoblast thromboxane production but did not affect prostacyclin production (Peaceman and Rehnberg, 1993) . The secretion of heparin-binding epidermal growth factor-like growth factor (HB-EGF) from trophoblasts was also decreased by treatment with aPL (Di Simone et al., 2010b) .
Other effects of aPL on trophoblasts
Coagulation
Two studies reported that aPL decreased the time taken to form a coagulum on trophoblast surfaces (Rand et al., 1997 (Rand et al., , 2010 . Six studies showed that aPL decreased the trophoblastic expression or secretion of annexin V, an anticoagulant protein (Table V) 
APS patient IgG
Normal human IgG 500 mg/ml IL-1b production ,0.05 CTB, cytotrophoblast; ab 2 GPI, anti-b 2 glycoprotein I antibody; SLE, systemic lupus erythematosus; APS, antiphospholipid syndrome; NHS, normal human serum; LA+ IgG, IgG antibodies from patient sera which show lupus anticoagulant activity; mAb, monoclonal antibody; IL, interleukin; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; IFNg, interferon-g; MIP-1a, macrophage inflammatory protein-1a; TNFa, tumour necrosis factor a; HB-EGF, heparin binding epidermal growth factor-like growth factor; VEGF, vascular growth factor; PIGF, placental growth factor; sFlt-1, soluble Fms-like tyrosine kinase-1; sEng, soluble endoglin.
a Observed with one of the two aPL used only.
Effects of aPL on trophoblasts in vitro
Complement activation
The effects of aPL on complement activation by trophoblasts were investigated by one study (Girardi et al., 2004) , which showed that aPL increased complement deposition on the surface of trophoblasts and also increased the production of soluble C3a desArg fragments, an pro-inflammatory effector molecule of the complement cascade.
The effect of treatment on the function of trophoblasts cultured with aPL
The anticoagulant drug heparin is commonly prescribed to women with the APS, either in low molecular weight or unfractionated forms. A total of nine studies investigated the effects of heparin on the function of trophoblasts cultured with aPL (Table VI) . Three studies showed that both unfractionated heparin and low molecular weight heparin (LMWH) prevented aPL from binding to the trophoblast surface (Di Simone et al., 1997 Simone et al., , 1999 Simone et al., , 2010b . However, another study reported that heparin did not affect the binding of aPL to trophoblasts (Girardi et al., 2004) . Other studies reported that heparin antagonized the detrimental effects of aPL on trophoblast syncytialization (Di Simone et al., 1999) , cell death (Bose et al., 2004; Mulla et al., 2009 ) and the production of hormones and cytokines (Di Simone et al., 1997 , 2010b Mulla et al., 2009 Mulla et al., , 2010 Han et al., 2011) . In addition, one study showed that heparin antagonized aPL-induced complement activation on the surface of trophoblasts (Girardi et al., 2004) . Three studies also showed that heparin antagonized the detrimental effect of aPL treatment on trophoblast invasion (Bose et al., 2004; Di Simone et al., 1999; Han et al., 2011) . However, one study reported that both low molecular weight and unfractionated heparin synergized with aPL to decrease trophoblast invasion (Mulla et al., 2010) .
Women with the APS may also be treated with aspirin. Four studies have investigated the effects of aspirin on the function of trophoblasts cultured with aPL (Table VI) . Two studies showed that aspirin did not affect the ability of aPL to bind trophoblasts (Di Simone et al., 1997 Simone et al., , 1999 . Furthermore, one of those studies also showed that aspirin had no beneficial effect on trophoblast invasion nor syncytialization in the presence of aPL (Di Simone et al., 1999) . In contrast, another study reported that aspirin antagonized the detrimental effects of aPL on trophoblast invasion . Aspirin may also have an effect on trophoblastic hCG secretion in the presence of aPL, although these effects may be concentration-dependent (Di Simone et al., 1997) .
The effects of anti-inflammatory drugs, such as indomethacin, betamethasone and pravastatin, on trophoblast function in the presence of aPL have also been studied. Indomethacin antagonized the detrimental effects of aPL on the secretion of prostacyclin and thromboxane by trophoblasts (Peaceman and Rehnberg, 1995) , and betamethasone antagonized the aPL-induced decrease in hCG secretion by trophoblasts Effects of aPL on trophoblasts in vitro (Di Simone et al., 1997) . Pravastatin did not affect trophoblast invasion in the presence of aPL in vitro (Odiari et al., 2012) , and its effects on cytokine production by aPL-treated trophoblasts were dependent on the type of trophoblast model employed (Table VI) . Five studies investigated whether antimalarial drugs can restore trophoblast function in the presence of aPL (Table VI) . One study showed that hydroxychloroquine inhibited the binding of aPL to trophoblasts in vitro (Wu et al., 2011) , while another study showed that chloroquine inhibited the internalization of aPL by trophoblasts . Two studies showed that hydroxychloroquine antagonized the aPL-induced decrease in annexin V expression on the surface of trophoblasts (Rand et al., 2010; Wu et al., 2011) and one study reported that hydroxychloroquine antagonized the aPL-induced inhibition of trophoblast invasion (Albert et al., 2013) . Another study reported that hydroxychloroquine antagonized the decrease in syncytialization induced by aPL (Marchetti et al., 2014) and one study showed that hydroxychloroquine prolonged the time to form a coagulum on the surface of trophoblasts in the presence of aPL (Rand et al., 2010) .
Discussion
This work has systematically reviewed the published literature that has investigated the in vitro effects of aPL on trophoblast function. There is strong evidence that aPL has a detrimental effect on trophoblast viability, syncytialization and invasion. Multiple studies also suggest that aPL alter the production of signalling molecules by trophoblasts and stimulate coagulation on the trophoblast surface. While there was strong evidence showing that aPL impair trophoblast function, there was limited in vitro evidence demonstrating that the detrimental effects of aPL on trophoblasts were reversed by current pharmacological treatments.
How do aPL affect trophoblast viability?
The results of this systematic review show that aPL negatively affect trophoblast proliferation and increase cell death (Fig. 2) . However, despite the large number of studies which reported these findings, few have delved into the mechanism behind this effect. Di Simone et al. (2006) showed that treatment of trophoblasts with aPL altered the expression of the apoptotic regulators, Bax and Bcl-2. While this finding may reflect the inhibitory effects of aPL on trophoblast syncytialization, it may also suggest that aPL treatment promotes trophoblast apoptosis. Another study showed that culturing trophoblasts with aPL decreased the expression of executioner caspases 3 and 7, suggesting that in addition to increasing trophoblast death, aPL may also alter the mechanism by which trophoblasts die, for example, through necrosis instead of apoptosis (Chen et al., 2009) . This hypothesis is supported by a transcriptomic analysis of placental explants, which showed the expression of TRAIL and other genes potentially involved in apoptosis to be down-regulated after treatment with aPL in vitro (Pantham et al., 2012) .
We have recently shown that aPL enter the syncytiotrophoblast by an antigen-specific receptor-mediated process , where they may target the mitochondria of the syncytiotrophoblast (Viall et al., 2014) . Both murine monoclonal and human polyclonal aPL disrupted mitochondrial function and increased the release of cytochrome c from the mitochondria . Since cytochrome c triggers the executioner stages of apoptosis (Finucane et al., 1999; Jiang and Wang, 2004) , this may be one mechanism by which aPL affect syncytiotrophoblast death.
How do aPL affect trophoblast syncytialization?
Syncytialization is another aspect of trophoblast function that is clearly reduced by aPL treatment in vitro (Fig. 2) . Fusion of cytotrophoblasts requires activation of initiator caspases and since aPL affect caspase expression in trophoblasts (Chen et al., 2009) , it is interesting to speculate that this may be the mechanism by which aPL affect trophoblast syncytialization. It has previously been reported that translocation of phosphatidylserine from the inner leaflet of the trophoblast membrane to the outer leaflet is required for syncytialization (Lyden et al., 1993) . However, a recent report showed that phosphatidylserine externalization is not key to trophoblast fusion and the rate of phosphatidylserine externalization can be independent from the rate of fusion (Riddell et al., 2013) .
Antiphospholipid antibodies also inhibited the production of hCG and other hormones by trophoblasts. This detrimental effect of aPL on the endocrine function of the syncytiotrophoblast may be secondary to aPL-impaired syncytialization. However, since the rate of hCG secretion by trophoblast cultures may not necessarily be reflective of trophoblastic fusion (Wice et al., 1990; Orendi et al., 2010) , it may be that aPL have a direct effect on the production of various hormones by trophoblasts.
How do aPL affect trophoblast invasion?
Antiphospholipid antibodies showed a robust negative effect on trophoblast invasion, which was demonstrated by all 14 studies that investigated trophoblast invasion in the presence of aPL in vitro. Trophoblast invasion is dependent upon the successful execution of many events, including the response of trophoblasts to cytokines, expression of adhesion molecules and breakdown of the basement membrane via secreted proteases (Graham and Lala, 1992) . Antiphospholipid antibodies may impair trophoblast invasion by causing down-regulation of a1 integrin and VE-cadherin, and up-regulation of a5 integrin and E-cadherin expression (Di Simone et al., 2002) as a1 integrin and VE-cadherin enhance cytotrophoblast invasiveness, while a5 integrin and E-cadherin restrain it (Damsky et al., 1994; Zhou et al., 1997) . In other studies, treatment of trophoblasts with aPL decreased the expression of matrix metalloproteinases (Di Simone et al., 2010b; Kovacevic et al., 2013) and increased the expression of inhibitors of metalloproteinases (Albert et al., 2013) . Combined, these changes are likely to contribute to the decreased invasion observed in trophoblasts treated with aPL.
Appropriate invasion by trophoblasts into the maternal decidua is crucial for a successful pregnancy. During the first trimester, if maternal spiral arteries are not sufficiently 'plugged' by endovascular trophoblasts, then strong streams of blood from these arteries may physically or oxidatively damage the placenta and contribute to early pregnancy loss (Burton and Jauniaux, 2011) . Later in gestation, if trophoblasts do not transform the maternal spiral arteries into wide-bore tubes adapted for efficient blood flow, the placenta may become underperfused and undergo ischemia-reperfusion injury (Fig. 3) . This may result in other pregnancy morbidities, such as pre-eclampsia and intrauterine growth restriction, which are associated with aPL (Sankaran and Kyle, 2009; Verlohren et al., 2010) .
How do aPL affect cytokine production by trophoblasts?
The production of cytokines by trophoblasts is important to consider for two reasons: (i) signs of inflammation may be present in placentae from women with the APS, indicative of pro-inflammatory changes in the placenta (Salafia and Parke, 1997; Stone et al., 2006) ; and (ii) cytokines can affect the uteroplacental environment and enter the maternal circulation to exert global effects on maternal systems.
Two studies reported that aPL increased the secretion of IL-1b by trophoblasts in vitro (Mulla et al., 2009, 2013) . Interleukin-1b is a pleiotropic cytokine that recruits monocytes and neutrophils, and activates macrophages (Ozaki et al., 1996; Oliveira et al., 2008; Wu et al., 2012) . In addition, IL-1b may increase trophoblast motility, as well as apoptosis (Nilkaeo and Bhuvanath, 2006; Prutsch et al., 2012; Wu et al., 2012) . Therefore, increased levels of IL-1b may not only affect the milieu of immune cells surrounding the developing placenta, but may also directly regulate trophoblast function and viability at a cellular level.
The trophoblastic secretion of other remote signalling molecules in the presence of aPL, for example, pro-inflammatory cytokines and antiangiogenic factors, has also been investigated (Table IV) . It is possible that alterations in the production of these factors by trophoblasts may play a Figure 2 Schematic representation of the effects of aPL on the placental villus. In the presence of aPL in vitro, cytotrophoblast proliferation is reduced while death is increased. This reduces the number of cytotrophoblasts underlying, and therefore available to replenish, the syncytiotrophoblast. Increased death of the syncytiotrophoblast also results in increased production of trophoblastic debris and potentially increased areas of syncytiotrophoblast denudation and fibrinoid deposition. Figure 3 Schematic representation of the effect of aPL on trophoblast invasion. Antiphospholipid antibodies reduce the ability of extravillous trophoblasts to invade into the maternal decidua, affecting both anchorage of the placenta, as well as reducing the transformation of maternal spiral arteries resulting in reduced maternal blood flow to the placenta.
Effects of aPL on trophoblasts in vitro role in the development of adverse outcomes in pregnancies affected by aPL. However, the secretion of these signalling molecules has only been reported in single studies, so there is currently insufficient evidence to draw meaningful conclusions.
How do aPL affect coagulation and complement activation at the placental interface?
There have been two studies which showed that aPL increased coagulation on trophoblast surfaces in vitro (Rand et al., 1997 (Rand et al., , 2010 . However, while aPL induce systemic thrombosis and were originally thought to increase fetal demise through increased thrombosis at the placental surface, the frequency of thrombosis at the materno-fetal interface in aPL-affected pregnancies is similar to that of healthy pregnancies (Lockshin et al., 1985; Sebire et al., 2002) . Therefore, it seems unlikely that placental thrombosis is a primary causal factor in fetal demise and other complications of the obstetric APS.
Only one study has reported on the effects of aPL on complement activation on trophoblasts in vitro (Girardi et al., 2004) . While studies using animal models are beyond the scope of this review, there is strong evidence from murine models of the APS that complement plays a crucial role in mediating fetal demise in murine aPL-affected pregnancies Salmon et al., 2002; Girardi et al., 2003; Redecha et al., 2007) . The complement proteins C3 and C5 have also been reported to be crucial for mediating aPL-induced thrombosis in mice (Pierangeli et al., 2005) . Placentae from women with the APS exhibit increased deposition of C4d and C3b, which supports the hypothesis that complement activation may be involved in the pathogenesis of pregnancy complications in women with aPL (Shamonki et al., 2007) . However, there are considerable differences in the control of the complement system at the materno-fetal interface between mice and women and additional human studies are required before a definitive conclusion regarding the role of complement in the obstetric APS can be made.
Can pharmacological treatments restore normal function in trophoblasts cultured with aPL?
The original rationale for treating patients with the APS using heparin was due to its anticoagulant properties and the misconception that aPL cause fetal demise by triggering thrombosis and infarction in the uteroplacental site (Quenby et al., 2004) . However, while heparin is successful in decreasing fetal loss in women with the APS, it is now well known that most women with the APS do not experience placental thrombosis (Lockshin et al., 1985; Salafia and Cowchock, 1997; Sheppard and Bonnar, 1981; Sebire et al., 2002) . Therefore, it is likely that heparin acts through other mechanisms to decrease fetal loss.
Three studies reviewed here suggest that heparin may prevent aPL from binding to trophoblasts (Di Simone et al., 1997 , 2010b . Several groups have shown in vitro that heparins can inhibit the binding of aPL to phospholipids (Guerin et al., 2002; Franklin and Kutteh, 2003) . This may be due to heparin inhibiting the binding of b 2 GPI to anionic phospholipids, thereby decreasing the available binding sites for aPL (Guerin et al., 2002) . Heparin can also inhibit the interaction between b 2 GPI and members of the low-density lipoprotein receptor family (Pennings et al., 2006) , receptors that are thought to play key role in the internalization of aPL by the syncytiotrophoblast .
Several studies summarized in this review also showed that heparin can antagonize the adverse effects of aPL on trophoblast death, syncytialization, complement activation and secretion of cytokines and hormones (Table VI) . Whether heparin has a protective effect on extravillous trophoblast function to reverse the adverse effects of aPL on invasion is less clear. From this review, it is also difficult to conclude whether unfractionated heparin or low molecular weight heparin is more beneficial in reversing the trophoblastic effects of aPL as limited studies have compared the effects of both in vitro.
Similarly, there is a lack of consensus in the reviewed studies as to what effects aspirin may have on aPL-treated trophoblasts in vitro. This observation corresponds with clinical trials that use aspirin to treat women with obstetric APS (systematically reviewed by Empson et al., 2002) . While there are clinical studies that show low-dose aspirin increasing the rate of successful births in pregnant women with the APS (Rai et al., 1997; Farquharson et al., 2002) and reducing the risk of pre-eclampsia (Duley et al., 2001) , there are also studies that suggest that aspirin treatment alone has no effect on pregnancy loss associated with the APS (Pattison et al., 2000) .
Other clinical treatment options for women with the APS have also been investigated in vitro, including antimalarial and anti-inflammatory drugs. Hydroxychloroquine is used to prevent lupus flares during pregnancy in women with aPL and no adverse effects on pregnancy have been reported (Parke and West, 1996; Levy et al., 2001; Clowse et al., 2006) . In mice injected with aPL, hydroxychloroquine significantly reduces the size of thrombi formed (Edwards et al., 1997; Espinola et al., 2002) . This review suggests that antimalarial drugs, such as hydroxychloroquine, may have beneficial effects on aPL-affected pregnancy by preventing aPL binding and antagonizing the deleterious effects of aPL on trophoblast fusion, invasion and coagulation on the trophoblast surface in vitro (Table VI) . These beneficial effects may be mediated in part by hydroxychloroquine decreasing b 2 GPI expression on the surface of trophoblasts which may in turn decrease the number of available sites for aPL binding (Marchetti et al., 2014) . In addition, hydroxychloroquine also decreases trophoblastic expression of TLR4 (Marchetti et al., 2014) , a receptor that may mediate some of the deleterious effects of aPL on trophoblast function (Mulla et al., 2009) .
In rodent models, treatment with the anti-inflammatory drug, pravastatin, decreases aPL-mediated fetal loss (Girardi, 2009; Redecha et al., 2009) , suggesting that it could be a promising treatment strategy. However, the beneficial effect of statins in human pregnancy is questionable, as the pathophysiological mechanisms of aPL-mediated fetal loss in mice and women may differ. Specifically, aPL-mediated fetal loss in mice is largely dependent on the activation of the complement cascade, yet in women, the involvement of the complement cascade in aPL-related fetal loss is less clear. The single study that investigated the effects of pravastatin on trophoblast function in vitro did not support a beneficial effect of pravastatin on trophoblast function (Odiari et al., 2012) .
Limitations of the studies included in this review
In many studies, less than ideal models of trophoblasts were used to study the effects of aPL on trophoblast function. For instance, results from studies that utilized immortalized trophoblast cell lines (BeWo, Jar, HTR8/SVneo, JEG-3 cells) must be interpreted with caution as trophoblast cell lines are rudimentary models of primary trophoblasts. Many studies also utilized term cytotrophoblasts to study the effects of aPL on trophoblast function and this may be inappropriate. For example, many studies used term cytotrophoblasts to study invasion, despite cytotrophoblasts from term placentae being remarkably noninvasive (Fisher et al., 1989) . Moreover, as pregnancy complications of the APS (recurrent miscarriage, pre-eclampsia and intrauterine growth restriction) have their pathogenic origins in the first trimester of pregnancy, it is important to focus on determining the effects of aPL on trophoblast models that are representative of early pregnancy.
The in vitro studies summarized in this review also used a large range of aPL concentrations, from 5 mg/ml (Di Simone et al., 2001) up to 100 mg/ml . The revised Sapporo criteria for the diagnosis of the APS require an antiphospholipid antibody level of over 20 mg/ml (Miyakis et al., 2006) . Whether the particularly low levels of aPL used in several studies that showed effects in vitro would translate into a clinical situation remains to be determined (Di Simone et al., 2001; Chen et al., 2009; Iwasawa et al., 2012; Kovacevic et al., 2013) . The level of purification of relevant antibodies is also highly variable between studies, ranging from non-purified patient sera to affinitypurified monoclonal antibodies. Therefore, it was hard to determine which studies accurately modelled pathologically relevant aPL levels.
The antigenic target of aPL is another important consideration that varied widely in the studies included in this systematic review. The revised Sapporo criteria for the diagnosis of the APS specify that clinically diagnostic aPL include the lupus anticoagulant and antibodies reactive with b 2 GPI or b 2 GPI/cardiolipin complexes (Miyakis et al., 2006) . Therefore, while studies involving non-criteria aPL, such as antiphosphatidylserine or antiannexin V antibodies, may be useful in understanding disease processes, caution must be taken when considering the clinical significance of studies employing such aPL (Katsuragawa et al., 1997; Vogt et al., 1997; Rote et al., 1998; Di Simone et al., 2001) .
Some of the discrepancies between in vitro studies may be explained by antibodies with differing epitope specificities (Hasegawa et al., 1990; Peaceman and Rehnberg, 1993; Chukwuocha et al., 2002; Schwartz et al., 2007) . This is illustrated by work which showed that two monoclonal aPL with epitopes both localized in the fifth domain of b 2 GPI had overlapping but also distinct effects on trophoblast function (Mulla et al., 2009; Viall et al., 2013) .
Limitations of this review
Since only published studies were available for inclusion, this review is susceptible to publication bias, which would skew the review towards aPL having a strong effect on trophoblast function. However, as many studies included in this review were qualitative in nature, a formal assessment of the possible extent of publication bias in this review is not possible.
This review focused on the direct effects of aPL on trophoblast function in vitro to elucidate the mechanisms by which aPL cause obstetric complications. However, aPL may also have adverse effects on other cell types which have not been considered in this review. For example, in vitro studies of rodent embryos have shown that aPL may be teratogenic and can affect early yolk sac development and outgrowth from blastocysts (Oksenberg and Brautbar, 1986; Abir et al., 1993; Sthoeger et al., 1993; Ornoy et al., 1998 Ornoy et al., , 2003 . Decidualization of the endometrium is another process which is critical to the success of pregnancy, and it has been shown that aPL can prevent progesterone-induced endometrial stromal cell decidualization (Mak et al., 2002) , secretion of eicosanoids by the decidua (Pierro et al., 1999) and endometrial angiogenesis (Di Simone et al., 2010a) . The ability of aPL to affect decidualization may alter the environment in which the placenta develops, thereby contributing to poor pregnancy outcomes in women with the APS (Frank et al., 1994; Lau et al., 1973) .
Recommendations for future in vitro studies
All in vitro studies, by necessity, use model systems and, by definition, no one model system is perfect. However, depending on the hypothesis tested, some models are more suitable than others and when conducting in vitro investigations into the pathogenic role of aPL in the future, researchers should consider which model is best to test the particular question or questions they are addressing. For example, since trophoblasts lose their invasive capacity as gestation increases, explants or isolated trophoblasts from first trimester placentae are optimal for invasion studies. However, there are ethical and practical issues around the supply and use of first trimester placentae such that the use of well-defined cells lines may be required. When possible, results with cell lines should be supported by experiments with primary trophoblasts. In contrast, syncytialization may be best studied using trophoblasts isolated from term placentae since term trophoblasts have a marked propensity to spontaneously syncytialize in culture.
With regard to the choice of antibodies, monoclonal aPL are extremely useful for mechanistic studies, since they can be produced in large quantities, with defined reactivity and guaranteed purity. However, monoclonal aPL cannot reflect the full heterogeneity/reactivity of polyclonal human aPL. Polyclonal aPL are extremely difficult to affinity-purify and most reports to date have employed IgG fractions containing aPL. While these IgG fractions are simple to isolate via affinity chromatography and are likely to reflect the full polyclonal reactivity of aPL, these fractions also contain many other antibodies that are not aPL and, as many patients with aPL will also have other autoantibodies in their serum, and such IgG fractions have the potential to produce effects that are unrelated to aPL. In future studies, it is important that researchers carefully consider the research question asked and use the most appropriate experimental design for their question(s) with justification for their choice of model systems.
Concluding remarks and future perspectives
Antiphospholipid antibodies are a large and diverse family of autoantibodies that may be pathological during pregnancy. However, the mechanisms by which aPL cause obstetric disease are still elusive. We have conducted this systematic review of the literature in an attempt to gain a better understanding of the effects of aPL on placental trophoblasts, the functions of which are essential to pregnancy. While there are some conflicting reports, we believe that our systematic review has reiterated the following effects of aPL on trophoblasts in vitro (Fig. 4) . (ii) Several studies have reported that aPL also affect the production of hormones, cytokines and other signalling molecules by trophoblasts in vitro. While the presence of increased inflammatory lesions on placentae from aPL-affected pregnancies have been reported (Van Horn et al., 2004; Stone et al., 2006) , we are not aware of any studies which have investigated the levels of pro-inflammatory cytokines present in the plasma of patients with obstetric APS. (iii) There is some evidence suggesting that aPL may affect coagulation and complement activation on trophoblasts in vitro. However, despite observations of reduced annexin V expression in placentae from aPL-affected pregnancies (Rand et al., 1994 (Rand et al., , 2004 , the general consensus from in vivo studies is that thrombosis and complement activation are unlikely to be the main mechanism by which aPL cause obstetric complications in women (Salafia and Cowchock, 1997; Sebire et al., 2002) .
While all of the studies included in this review reported on changes in trophoblast function with aPL treatment, few have investigated the intracellular pathways affected by aPL to elicit these changes. This approach is required to further increase our understanding of how aPL affect trophoblast function and viability. Gleicher et al. (1992) began this investigation by proposing that aPL neutralize phospholipids on the cell surface which may affect intracellular signalling, as many phospholipids are substrates for phospholipase signalling (Gleicher et al., 1992) . Antiphospholipid antibodies have also been reported to affect the formation of the annexin V lattice on the trophoblast surface (Rand et al., 1997a (Rand et al., , b, 2003 Wu et al., 2011) , which may promote coagulation and affect trophoblast function. Mechanistically, aPL may affect syncytiotrophoblast function or viability by penetrating this cell and causing mitochondrial dysfunction . Conversely, in other trophoblast populations, aPL may exert detrimental cellular effects by signalling through the innate immune receptor, TLR4, (Mulla et al., 2009 Marchetti et al., 2014) and triggering activation of the NALP3 inflammasome . Similar mechanistic approaches in appropriate experimental models are required in the future to understand exactly how aPL cause trophoblast dysfunction. It is clear from this systematic review of the published in vitro effects of aPL that much work remains to be done. Figure 4 Schematic representation of the major effects of aPL on trophoblast function in vitro. There is strong in vitro evidence suggesting that aPL can increase trophoblast death, reduce syncytialization and invasion, as well as affect protein production by trophoblasts (solid boxes). There is also some in vitro evidence that aPL reduce trophoblast proliferation while increasing coagulation and complement activation (dotted boxes).
